The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Relay Therapeutics Inc shares valued at $219,123 were sold by Patel Sanjiv on Jul 09 ’25. At $3.57 per share, Patel Sanjiv sold 61,379 shares. The insider’s holdings dropped to 765,288 shares worth approximately $2.79 million following the completion of this transaction.
Also, Rahmer Peter sold 10,739 shares, netting a total of over 32,217 in proceeds. Following the sale of shares at $3.00 each, the insider now holds 390,081 shares.
Before that, Rahmer Peter had sold 1,364 shares from its account. In a trade valued at $4,324, the insider traded Relay Therapeutics Inc shares for $3.17 each. Upon closing the transaction, the insider’s holdings decreased to 1,364 shares, worth approximately $1.46 million.
As published in their initiating research note from Wells Fargo on April 17, 2025, Relay Therapeutics Inc [RLAY] has been an Equal weight and the price target has been revised to $4. Analysts at Jefferies upgraded the stock from ‘”a Hold”‘ to ‘”a Buy”‘ outlook in a report released in early September. Earlier on September 10, 2024, Oppenheimer downgraded its rating. Their new recommendation was “a Perform” for RLAY stock which previously was a “an Outperform”.
Analyzing RLAY Stock Performance
On last trading session,, Relay Therapeutics Inc [NASDAQ: RLAY] rose 0.27% to $3.65. The stock’s lowest price that day was $3.625, but it reached a high of $3.795 in the same session. During the last five days, there has been a drop of approximately -2.14%. Over the course of the year, Relay Therapeutics Inc shares have dropped approximately -55.86%.
Support And Resistance Levels for Relay Therapeutics Inc (RLAY)
RSI (Relative Strength Index) is 58.18 on the 14-day chart, showing neutral technical sentiment.
Is Relay Therapeutics Inc subject to short interest?
Stocks of Relay Therapeutics Inc saw a sharp steep in short interest on 2025-06-13 dropping by -0.63 million shares to 22.52 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 23.16 million shares. A decline of -2.82% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 16.1 of the overall float, the days-to-cover ratio (short ratio) decline to 16.1.
Which companies own the most shares of Relay Therapeutics Inc (RLAY)?
In terms of Relay Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 19 in the next 12 months, up nearly 421.98% from the previous closing price of $3.64. Analysts anticipate Relay Therapeutics Inc stock to reach 25 by 2025, with the lowest price target being 16. In spite of this, 8 analysts ranked Relay Therapeutics Inc stock as Buy at the end of 2025. On May 10, 2024, Barclays assigned a price target of “an Overweight” to the stock and upgraded coverage with a $15.
